vs
爱尔康（ALC）与Cooper Companies (The)（COO）财务数据对比。点击上方公司名可切换其他公司
爱尔康的季度营收约是Cooper Companies (The)的2.4倍（$2.6B vs $1.1B）。Cooper Companies (The)净利率更高（7.9% vs 6.8%，领先1.2%）。Cooper Companies (The)同比增速更快（4.6% vs 4.0%）
爱尔康是瑞美合资的制药及医疗器械企业，专注于眼健康护理产品领域。公司注册地为瑞士弗里堡州，全球总部设于日内瓦，核心运营基地位于美国得克萨斯州沃思堡，当地员工规模约4500人。
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
ALC vs COO — 直观对比
营收规模更大
ALC
是对方的2.4倍
$1.1B
营收增速更快
COO
高出0.6%
4.0%
净利率更高
COO
高出1.2%
6.8%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.6B | $1.1B |
| 净利润 | $176.0M | $84.6M |
| 毛利率 | 53.5% | 61.1% |
| 营业利润率 | 9.5% | 13.2% |
| 净利率 | 6.8% | 7.9% |
| 营收同比 | 4.0% | 4.6% |
| 净利润同比 | -21.1% | -28.0% |
| 每股收益（稀释后） | $0.35 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALCCOO
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $2.6B | $1.0B | ||
| Q1 25 | — | $964.7M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | $2.5B | $942.6M | ||
| Q1 24 | — | $931.6M |
净利润ALCCOO
| Q4 25 | — | $84.6M | ||
| Q3 25 | — | $98.3M | ||
| Q2 25 | $176.0M | $87.7M | ||
| Q1 25 | — | $104.3M | ||
| Q4 24 | — | $117.5M | ||
| Q3 24 | — | $104.7M | ||
| Q2 24 | $223.0M | $88.9M | ||
| Q1 24 | — | $81.2M |
毛利率ALCCOO
| Q4 25 | — | 61.1% | ||
| Q3 25 | — | 65.3% | ||
| Q2 25 | 53.5% | 67.8% | ||
| Q1 25 | — | 68.4% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 66.1% | ||
| Q2 24 | 55.0% | 67.0% | ||
| Q1 24 | — | 67.0% |
营业利润率ALCCOO
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | 16.6% | ||
| Q2 25 | 9.5% | 18.4% | ||
| Q1 25 | — | 18.9% | ||
| Q4 24 | — | 19.5% | ||
| Q3 24 | — | 19.2% | ||
| Q2 24 | 12.7% | 17.2% | ||
| Q1 24 | — | 16.4% |
净利率ALCCOO
| Q4 25 | — | 7.9% | ||
| Q3 25 | — | 9.3% | ||
| Q2 25 | 6.8% | 8.7% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 11.5% | ||
| Q3 24 | — | 10.4% | ||
| Q2 24 | 8.9% | 9.4% | ||
| Q1 24 | — | 8.7% |
每股收益（稀释后）ALCCOO
| Q4 25 | — | $0.42 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | $0.35 | $0.44 | ||
| Q1 25 | — | $0.52 | ||
| Q4 24 | — | $0.59 | ||
| Q3 24 | — | $0.52 | ||
| Q2 24 | $0.45 | $0.44 | ||
| Q1 24 | — | $0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $110.6M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $22.1B | $8.2B |
| 总资产 | $31.4B | $12.4B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ALCCOO
| Q4 25 | — | $110.6M | ||
| Q3 25 | — | $124.9M | ||
| Q2 25 | $1.4B | $116.2M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $107.6M | ||
| Q3 24 | — | $109.7M | ||
| Q2 24 | $1.4B | $112.4M | ||
| Q1 24 | — | $135.2M |
总债务ALCCOO
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
股东权益ALCCOO
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | $8.4B | ||
| Q2 25 | $22.1B | $8.3B | ||
| Q1 25 | — | $8.1B | ||
| Q4 24 | — | $8.1B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | $20.9B | $7.8B | ||
| Q1 24 | — | $7.7B |
总资产ALCCOO
| Q4 25 | — | $12.4B | ||
| Q3 25 | — | $12.4B | ||
| Q2 25 | $31.4B | $12.4B | ||
| Q1 25 | — | $12.2B | ||
| Q4 24 | — | $12.3B | ||
| Q3 24 | — | $12.1B | ||
| Q2 24 | $29.7B | $12.0B | ||
| Q1 24 | — | $12.0B |
负债/权益比ALCCOO
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $247.9M |
| 自由现金流经营现金流 - 资本支出 | — | $149.9M |
| 自由现金流率自由现金流/营收 | — | 14.1% |
| 资本支出强度资本支出/营收 | — | 9.2% |
| 现金转化率经营现金流/净利润 | — | 2.93× |
| 过去12个月自由现金流最近4个季度 | — | $433.7M |
8季度趋势，按日历期对齐
经营现金流ALCCOO
| Q4 25 | — | $247.9M | ||
| Q3 25 | — | $261.4M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $190.6M | ||
| Q4 24 | — | $268.1M | ||
| Q3 24 | — | $207.5M | ||
| Q2 24 | — | $111.0M | ||
| Q1 24 | — | $122.7M |
自由现金流ALCCOO
| Q4 25 | — | $149.9M | ||
| Q3 25 | — | $164.5M | ||
| Q2 25 | — | $18.1M | ||
| Q1 25 | — | $101.2M | ||
| Q4 24 | — | $128.1M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $36.9M | ||
| Q1 24 | — | $4.6M |
自由现金流率ALCCOO
| Q4 25 | — | 14.1% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 12.6% | ||
| Q3 24 | — | 11.8% | ||
| Q2 24 | — | 3.9% | ||
| Q1 24 | — | 0.5% |
资本支出强度ALCCOO
| Q4 25 | — | 9.2% | ||
| Q3 25 | — | 9.1% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 9.3% | ||
| Q4 24 | — | 13.7% | ||
| Q3 24 | — | 8.9% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 12.7% |
现金转化率ALCCOO
| Q4 25 | — | 2.93× | ||
| Q3 25 | — | 2.66× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 1.83× | ||
| Q4 24 | — | 2.28× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 1.25× | ||
| Q1 24 | — | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALC
暂无分部数据
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
